<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091725</url>
  </required_header>
  <id_info>
    <org_study_id>201612107</org_study_id>
    <secondary_id>UL1TR000448</secondary_id>
    <secondary_id>KL2TR000450</secondary_id>
    <nct_id>NCT03091725</nct_id>
  </id_info>
  <brief_title>A Role for FGF21 in Postprandial Nutrient Homeostasis After RYGB</brief_title>
  <acronym>FGB</acronym>
  <official_title>A Role for FGF21 in Postprandial Nutrient Homeostasis After RYGB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bariatric surgery markedly improves glycemic control in persons with Type 2 Diabetes (T2D).&#xD;
      Roux-en-Y gastric bypass (RYGB), a procedure that bypasses the upper gastrointestinal (UGI)&#xD;
      tract, results in greater rates of diabetes resolution compared to methods that leave the UGI&#xD;
      tract intact. Studies suggest that mechanisms beyond weight-loss account for the superiority&#xD;
      of RYGB compared to other surgical methods. These weight-loss independent metabolic effects&#xD;
      may involve increased postprandial production and release of nutrition- responsive hormones.&#xD;
      Fibroblast growth factor 21 (FGF21) is a nutrition-adaptive hormone with the potential to&#xD;
      alleviate symptoms of diabetes and obesity. Preliminary data therefore suggest that RYGB&#xD;
      surgery may alter postprandial FGF21 regulation which could be important for achieving&#xD;
      post-meal nutrient homeostasis. Therefore, the goal of this study is to test how nutrient&#xD;
      content of the meal affects FGF21 concentrations before and after weight loss induced by RYGB&#xD;
      or very low calorie diet (VLCD) therapy. The importance of FGF21 for glucose, insulin,&#xD;
      triglyceride, and adipose tissue and muscle metabolism in these two groups will also be&#xD;
      tested.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial FGF21 plasma concentrations</measure>
    <time_frame>9 months</time_frame>
    <description>Concentrations of FGF21 protein will be measured in plasma after consuming a high glucose meal or a high fat meal, before and after surgery or low calorie diet.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>RYGB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group are scheduled to undergo Roux-en-Y gastric bypass surgery and will be assessed after 16-18% weight-loss</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLCD Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group will participate in a very low-calorie diet intervention to obtain a 16-18% weight loss.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en-Y gastric bypass surgery</intervention_name>
    <description>A bariatric surgery procedure which will help individuals achieve 16-18% weight loss</description>
    <arm_group_label>RYGB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Very low-calorie diet</intervention_name>
    <description>Subjects will meet with a dietitian and/or behaviorist over 4-6 months to lose 16-18% of their body weight.</description>
    <arm_group_label>VLCD Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Surgery Group (RYGB):&#xD;
&#xD;
          -  Males and Females&#xD;
&#xD;
          -  Scheduled for RYGB surgery&#xD;
&#xD;
          -  Body Mass Index 35-55 kg/m²&#xD;
&#xD;
          -  Without Type 2 Diabetes (T2D)&#xD;
&#xD;
        VLCD group:&#xD;
&#xD;
          -  Males and Females&#xD;
&#xD;
          -  Body Mass Index 35-55 kg/m²&#xD;
&#xD;
          -  Without Type 2 Diabetes (T2D)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Surgery Group (RYGB):&#xD;
&#xD;
          -  Regular use of tobacco products&#xD;
&#xD;
          -  Previous intestinal resection&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Evidence of significant organ system dysfunction or disease other than obesity and T2D&#xD;
&#xD;
          -  Use of any medication that might, in the opinion of the investigator, affect metabolic&#xD;
             function&#xD;
&#xD;
          -  Exercise ≥90 minutes per week&#xD;
&#xD;
          -  Use or past use of hormone replacement therapy within the past 6 months&#xD;
&#xD;
        VLCD Group:&#xD;
&#xD;
          -  Regular use of tobacco products&#xD;
&#xD;
          -  Previous intestinal resection&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Evidence of significant organ system dysfunction or disease other than obesity and T2D&#xD;
&#xD;
          -  Use of any medication that might, in the opinion of the investigator, affect metabolic&#xD;
             function&#xD;
&#xD;
          -  Exercise ≥90 minutes per week&#xD;
&#xD;
          -  Use or past use of hormone replacement therapy within the past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lydia-Ann Harris, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>314-362-8708</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Roux-en-Y gastric bypass (RYGB)</keyword>
  <keyword>Very low calorie diet</keyword>
  <keyword>Fibroblast growth factor 21 (FGF21)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

